MDxHealth S.A. (MDXH)
Healthcare
- Fundamental
- 2
- Sentiment
- 1
- Technical
- 3
Do Nothing: fundamentalScore 2 and qualitativeScore 1 are below the required floor of 3, and recent 3-session average dollar volume (~$0.37M) is below the $1.5M recent-liquidity floor.
Company overview
MDxHealth SA is a precision diagnostics company specializing in urologic solutions, with a focus on prostate cancer genomic testing. Its products, including SelectMDx and ConfirmMDx, aim to reduce reliance on invasive procedures. The company operates internationally, with headquarters in Herstal, Belgium.
Fundamental
weakMDxHealth shows revenue growth but remains loss-making with high financing burden and going-concern risks.
Rapid revenue growth and strong gross margins are the bright spots, and operating cash burn improved markedly versus prior years. But the company remains loss-making with high financing burden, negative equity in the latest interim balance sheet, and an explicit going-concern/substantial-doubt disclosure in the FY2025 annual report. A recent August 2026 equity raise improves liquidity but is meaningfully dilutive and highlights ongoing funding reliance, keeping fundamentals in the high-risk bucket.
Sentiment
very weakSentiment is cautious due to dilution and compliance concerns despite recent revenue growth.
Media sentiment in the last ~14 days turned constructive around the Aug-2026 Q2 results and the ~$20M share offering (company-announced), with sentiment improving versus the prior 30–90 day window (polarity_score ≈ +0.30 vs ≈ -0.08). A severe red-flag cap applies due to prior going-concern disclosures and ongoing dilution/listing-compliance overhang despite the near-term narrative improvement.
Technical
fairThe stock shows short-term momentum but remains in a high-volatility post-catalyst consolidation.
Score 3/5: MDXH is above its SMA20 (0.54), SMA50 (0.5), EMA9 (0.68), EMA21 (0.58), and daily VWAP (0.73), while RSI14 (65.71), MACD (0.07 vs 0.03 signal), and ADX14 (55.45) support a short-term rebound. Offsetting that, the stock remains far below the SMA200 (2.27), ATR14 is about 12.0% of price, and recent regular-session liquidity has dried up after the 8/14 catalyst spike.
You’re looking at 2026-08-22 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.